Status and phase
Conditions
Treatments
About
This is a phase 2, Open-label, to investigate the efficacy and safety of IMC-001 in patients with Relapsed or Refractory extranodal NK/T cell lymphoma, nasal type
Full description
IMC-001 is a PD-L1 targeting, fully human monoclonal antibody. The purpose of this study is to determine and evaluate the efficacy and safety of IMC-001. 20mg/kg every 2 weeks, IV infusion of IMC-001 will be tested in subjects with Relapsed or Refractory extranodal NK/T cell lymphoma, nasal type.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
ENKTL diagnosis;
Adult age(as defined by respective country)
The nature of the study and voluntarily sign an ICF
ECOG 0 or1
Adequate hematologic function, hepatic function, and renal function
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
23 participants in 1 patient group
Loading...
Central trial contact
MinYoung Son; JiEun Oh
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal